Expression of a recombinant protein, A2 family, from *Leishmania infantum* (Jaboticabal strain) and its evaluation in Canine Visceral Leishmaniasis serological test

*Márcia Mariza Gomes Jusi*¹; *Trícia Maria Ferreira de Sousa Oliveira*²; *Andrêa Cristina Higa Nakaghi*³; *Marcos Rogério André*¹; *Rosangela Zacarias Machado*¹*

¹Laboratório de Imunoparasitologia, Departamento de Patologia Veterinária, Faculdade de Ciências Agrárias e Veterinárias, Universidade Estadual Paulista – UNESP, Jaboticabal, SP, Brasil
²Departamento de Zootecnia, Faculdade de Zootecnia e Engenharia de Alimentos, Universidade de São Paulo – USP, Pirassununga, SP, Brasil
³Faculdade de Ciências Agrárias e Sociais, Iapecv, SP, Brasil

Received February 23, 2015
Accepted April 16, 2015

Abstract

This study aimed to: express a recombinant A2 family protein of *Leishmania chagasi*, Jaboticabal strain; test this protein as an antigen in serological assays; and investigate its antigenicity and immunogenicity. A protein coded by an allele of the A2 gene isolated from *L. chagasi* was expressed in three different strains of *Escherichia coli*. We used 29 sera samples from Leishmune-vaccinated dogs, 482 sera samples from dogs from endemic areas (positive controls), and 170 sera samples from dogs from non-endemic areas (negative controls) in ELISA tests using soluble *Leishmania* antigen (SLA) and His-A2 as antigen. Expressed proteins showed, by western blotting, the expression of an 11 KDa protein. Sixty-three percent (303/482) of the samples from endemic areas were positive by ELISA His-A2, whereas 93.1% (27/29) of Leishmune-vaccinated animals were negative by His-A2-ELISA. Anti-A2 antibodies from mice inoculated with the A2 protein were detected in slides containing amastigote forms, but not in slides containing promastigote forms. The A2 recombinant protein from *L. chagasi* may be a useful tool in the diagnosis of CVL, and further tests regarding the infection stage and the specie of parasite at which the dogs are sampled should provide a better understanding of our results.

Keywords: *Leishmania infantum*, A2, *Escherichia coli*, diagnosis, ELISA.
Introduction

Over 90% of visceral leishmaniasis cases (also called Kalazar) occur in Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan. This disease is caused by *Leishmania infantum*, which belongs to the *Leishmania donovani* complex (WHO, 2014), and, in Brazil, is mainly transmitted by the sandy fly *Lutzomyia longipalpis* (Diptera: Psychodidae), although *Lutzomyia cruzi* has also been described as a potential vector (TRAVI et al., 2002; SANTOS et al., 1998).

Although visceral leishmaniasis (VL) also occurs in humans, its prevalence is much higher in dogs than in humans (ALENCAR, 1978). Moreover, dogs have a greater number of skin parasites compared to humans, which promote infection by blood-sucking sand flies (TRAVI et al., 2001; QUEIROZ et al., 2010; JUSI et al., 2011). Therefore, dogs play an important role in contributing to our understanding of CVL epidemiology.

The diagnosis of CVL is difficult because dogs present variety of clinical signs and many dogs are asymptomatic; also there is currently no test for CVL with 100% specificity and sensitivity (GENARO, 1993). Serological tests such as Indirect Fluorescence Antibody Test (IFAT), Enzyme-Linked Immunosorbent Assays (ELISAs), dot-ELISA, Direct Agglutination Test, Western Blotting, and the Lateral Immunochromatographic test are commonly used for diagnosing CVL. In Brazil, one of the most employed methods for controlling CVL is based on the removal of seropositive dogs for *Leishmania* spp., which has been questioned by several authors (PARANHOS-SILVA et al., 1998; COURTENAY et al., 2002). Nunes et al. (2010) point out that the euthanasia of dogs has reduced human infections, but the authors also indicate the need for other preventive measures for the success of this measure such as vector control and treatment of infected humans.

Recombinant antigens such as “A2” and “K39” have been assessed in an attempt to develop simpler, faster, and more specific serological diagnosis for leishmaniasis. Charest & Matlashewski (1994) isolated and expressed a protein from the A2 multigene family from *L. donovani infantum*, which was recognized by 60% and 82% of humans with visceral leishmaniasis (VL) in India and Sudan, respectively, using ELISA. Moreover, Carvalho et al. (2002) also showed a high prediction of a signal peptide in the first 26 amino acids out of a total 114 amino acids. After exclusion of the signal peptide nucleotide sequence, primers A2b reverse and A2c forward were designed, aiming to include the *ND1* and *EcoR* enzyme restriction sites, respectively. PCR cycles consisted of an initial denaturation at 94°C for 2 min followed by 25 amplification cycles at 94°C for 1 min, 51°C for 1 min, 72°C for 1 min, followed by a final extension cycle at 72°C for 7 min. The A2b/A2c-PCR product was purified using the Silica Bead DNA Gel Extraction Kit (Fermentas Cat #K0513) and DNA concentration was measured using a Nanodrop ND1000 spectrophotometer (Thermo Scientific, USA). This cloned gene was used as a template in PCR to amplify the A2 gene using 0.5 µM of the specific primers designed in this study. Analyses using the SignalP 3.0 Program (BENDTSEN et al., 2004) showed a high prediction of a signal peptide in the first 26 amino acids out of a total 114 amino acids. After exclusion of the signal peptide nucleotide sequence, primers A2b reverse (5’ AGAATTCTTAAGACACCGGGAGAACGT C3’) and A2c forward (5’ ACATATGGTCTAGCCCGACAAGGC 3’) were designed, aiming to include the *ND1* and *EcoR* enzyme restriction sites, respectively. PCR cycles consisted of an initial denaturation at 94°C for 2 min followed by 25 amplification cycles at 94°C for 1 min, 51°C for 1 min, 72°C for 1 min, followed by a final extension cycle at 72°C for 7 min. The A2b/A2c-PCR product was purified using the Silica Bead DNA Gel Extraction Kit (Fermentas Cat # K0513) and DNA concentration was measured using a Nanodrop ND1000 spectrophotometer (Thermo Scientific, USA). This purified amplified product was subcloned into a pGEM-T Easy vector system (Promega, Madison, USA). The cloning vector containing the desirable DNA insert was transformed using the One Shot Match 1™-T1® Chemically Competent Cells (Invitrogen, Carlsbad, USA). The transformants were analyzed by restriction analysis and DNA sequencing. Next, the target DNA was subcloned into a pET 28a expression vector (Novagen, USA) using *EcoR* and *Nd1* sites. The *pET* 28a-A2 containing the target-sequence was transformed into three different *E. coli* strains, named BL21 (DE3), ER2566, and Rosetta competent cells. To confirm the correct direction of this construction, a PCR using the A2b reverse primer and T7 promoter primer from pET 28a vector (5’ – TAATACGACTCACA TAGGG – 3’) was

Materials and Methods

Strain and gene isolation

A strain of *L. infantum* was isolated by Machado and Tinucci-Costa (unpublished data) from a dog showing clinical signs of CVL attended at Governador Laudo Natel Veterinary Hospital in Jaboticabal, São Paulo, Brazil (OLIVEIRA et al., 2011). The dog, originally from the city of Olimpia, in the state of São Paulo, showed positive results in serological (IFAT and ELISA) (OLIVEIRA et al., 2008) and molecular (MICHALSKY et al., 2002; CORTESE et al., 2004) tests for *Leishmania infantum* was isolated in culture from bone marrow in RPMI medium (Sigma) supplemented with 20% heat-inactivated fetal calf serum (Gibco BRL), penicillin (100 U/ml), and streptomycin (50 mg/ml) and used to isolate the A2 gene. Previously, an identical 504-nucleotide A2-gene sequence [Genbank:GQ290460] was isolated in two clones from the genomic library of *L. infantum* (OLIVEIRA et al., 2011).

Cloning, expression, and purification of the A2 recombinant protein

The A2 gene allele was isolated by Oliveira et al. (2011) and cloned into a pGEM-T Easy vector system (Promega, Madison, USA). This cloned gene was used as a template in PCR to amplify the A2 gene using 0.5 µM of the specific primers designed in this study. Analyses using the SignalP 3.0 Program (BENDTSEN et al., 2004) showed a high prediction of a signal peptide in the first 26 amino acids out of a total 114 amino acids. After exclusion of the signal peptide nucleotide sequence, primers A2b reverse (5’ AGAATTCTTAAGACACCGGGAGAACGT C3’) and A2c forward (5’ ACATATGGTCTAGCCCGACAAGGC 3’) were designed, aiming to include the *ND1* and *EcoR* enzyme restriction sites, respectively. PCR cycles consisted of an initial denaturation at 94°C for 2 min followed by 25 amplification cycles at 94°C for 1 min, 51°C for 1 min, 72°C for 1 min, followed by a final extension cycle at 72°C for 7 min. The A2b/A2c-PCR product was purified using the Silica Bead DNA Gel Extraction Kit (Fermentas Cat #K0513) and DNA concentration was measured using a Nanodrop ND1000 spectrophotometer (Thermo Scientific, USA). This purified amplified product was subcloned into a pGEM-T easy vector system (Promega, Madison, USA). The cloning vector containing the desirable DNA insert was transformed using the One Shot Match 1™-T1® Chemically Competent Cells (Invitrogen, Carlsbad, USA). The transformants were analyzed by restriction analysis and DNA sequencing. Next, the target DNA was subcloned into a pET 28a expression vector (Novagen, USA) using *EcoR* and *Nd1* sites. The *pET* 28a-A2 containing the target-sequence was transformed into three different *E. coli* strains, named BL21 (DE3), ER2566, and Rosetta competent cells. To confirm the correct direction of this construction, a PCR using the A2b reverse primer and T7 promoter primer from pET 28a vector (5’ – TAATACGACTCACA TAGGG – 3’) was
performed. The induction of expression of the histidine-tagged recombinant protein (His6-A2) was performed in LB medium containing 0.2% glucose and 50 µg/mL kanamycin. The expression of His-A2 (11 kDa) was induced by 0.5 mM IPTG (Isopropyl-β-D-thiogalactopyranoside, Thermo Scientific) at 250 rpm and 37 °C. Samples of the bacteria extract were collected after 6 h for ER2266 and Rosetta and after 3 h for BL21. Protein expression was analyzed by 12% sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE) (LAEMMLI, 1970) and Western-blotting (TOWBIN et al., 1979), using the polyclonal anti-histidine mouse antibody (Sigma, St. Louis, USA).

Canine sera samples

A total of 681 canine sera samples were used for evaluation of the His6-A2-ELISA:

(i) **Negative controls**: included 170 dogs sampled from Jaboticabal (21° 15’ 17” S/48° 19’ 20” W), state of São Paulo, a non-endemic area for CVL. These dog sera samples previously showed negative results for *L. infantum* using serologic methods (IFAT/ELISA).

(ii) **Positive controls**: included 482 dogs sampled from endemic areas for CVL in Campo Grande (20° 26’ 34” S/54° 38’ 47” W), state of Mato Grosso do Sul, state of Tocantins (10° 12’ 46” S/51° 20’ 33” W), and Ilha Solteira, state of São Paulo (20° 25’ 58” S/51° 20’ 33” W). These dog sera samples previously showed positive results for *L. infantum* in serologic methods (IFAT/ELISA).

(iii) **Vaccinated dogs (Leishmune® [Fort Dodge]):** included 29 Leishmune® vaccinated dogs, whose sera samples were kindly supplied by Fort Dodge Animal Health Company, USA.

**ELISA using Soluble Leishmania Antigen (SLA)**

The ELISA method used was the one described by Oliveira et al. (2008) for *L. infantum* with a few modifications. Microtiter immunoassay plates (Polysorp Nunclon™ Surface. Nunc, Denmark) were coated with soluble *Leishmania* antigens (SLA) (10 µg/mL of protein concentration) in 100 µL of sodium bicarbonate-carbonated 0.05M buffer (pH 9.6) for 18 h at 4 °C. After this procedure the plates were washed three times with 0.05% PBS Tween 80 (PBST). Free binding sites were blocked with 2% nonfat dry milk solution for 2 h at 37 °C. After three washes with 0.05% PBST, plates were incubated (1 h at 37 °C) with 100 µL of alkaline phosphatase conjugated anti-dog IgG (Sigma, St. Louis, USA) diluted 1:100, and 1:200 in PBST with 2, 3, and 5% nonfat dry milk for each dilution. One hundred µL of alkaline phosphatase conjugated anti-dog IgG (Sigma-Aldrich, St. Louis, USA) diluted at 1: 4 000 in PBS Tween-20 with 5% nonfat dry milk was added to each well, followed by incubation for 60 minutes at 37 °C. Plates were washed and a 100 µL diethanolamine solution (pH 9.8) containing a substrate for phosphatase (4-nitrophenyl phosphate disodium salt hydrate, Sigma) was added into each well. Absorbance of each serum sample was measured after 30 min of incubation at room temperature using an ELISA reader at 405 nm (Dynex Technologies, USA). The discriminating absorbance value (cut-off) was determined as being equal to two and a half times the mean absorbance value of the negative group (OLIVEIRA et al., 2008), whereas values equal to or greater than the cut-off value were considered positive.

**ELISA using the A2 protein recombinant as antigen**

Microtiter immunoassay plates (Maxisorp Nunclon™ Surface. Nunc, Denmark) were coated with His6-A2 recombinant protein (protein concentration was adjusted to 2.5, 5, 10, 20, and 40 µg/mL) in 100 µL of sodium bicarbonate-carbonated 0.05M buffer (pH 9.6) for 18 h at 4 °C. After this procedure the plates were washed three times with 0.05% PBS Tween 80 (PBST). Free binding sites were blocked with 2% nonfat dry milk solution for 2 h at 37 °C. After three washes with 0.05% PBST, plates were incubated (1 h at 37 °C) with 100 µL positive and negative canine sera samples (previously determined with IFAT), diluted 1:50, 1:100, and 1:200 in PBST with 2, 3, and 5% nonfat dry milk for each dilution, followed by incubation for 60 minutes at 37 °C. Plates were washed and a 100 µL diethanolamine solution (pH 9.8) containing a substrate for phosphatase (4-nitrophenyl phosphate disodium salt hydrate, Sigma) was added into each well. Absorbance of each serum sample was measured after 45 min incubation at room temperature using an ELISA reader at 405 nm (Dynex Technologies, USA). The discriminating absorbance value (cut-off) was determined as being equal to two and a half times the mean absorbance value of the negative group (OLIVEIRA et al., 2008), whereas values equal to or greater than the cut-off value were considered positive. ELISA results are presented as ELISA levels, to this, the optical density for the antigen-antibody reaction of each serum from each animal was ranked from 0 (lowest level) to 9 (highest level) using optical density (OD) intervals, as described by Machado et al. (1997).

**Western blot analysis**

Expressed unpurified protein extract and purified recombinant protein were separated by electrophoresis (Mini-Protean II, Bio-Rad, Hercules, CA, USA) in a 12% gradient polyacrylamide gel with sodium dodecyl sulfate (LAEMMLI, 1970). The transfer to nitrocellulose membranes was performed as previously described (TOWBIN et al., 1979). Membranes were blocked with 5% nonfat dry milk and 0.05% Tween-20 in Tris buffered saline (TBS: 20 mM Tris, 500 mM NaCl, pH 7.5) for 12 h at 4 °C. For immunodetection, nitrocellulose membranes were assayed with monoclonal anti-polyhistidine (Sigma, St. Louis, USA) diluted at 1: 3 000 in PBS-Tween with 5% nonfat dry milk for 1 h at room temperature. Next, membranes were washed three times (10 min each) with TBS-Tween and incubated with IgG anti-mouse alkaline phosphatase conjugate (Sigma, St. Louis, USA).
USA, cat. A-3562) for 90 min. Conjugate was removed and three washes (10 min each) were performed using TBS-Tween. The polypeptide bands were visualized by the addition of the enzyme substrate 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium chloride (NBT-BCIP, Bio-Rad, Hercules, CA, USA). Colorimetric reactions were stopped by washing the membranes in distilled water.

**Mice**

His6-A2 (10 mg) immunogenicity was verified by immunization of six- to eight-week old SPF BALB/c mice (MACHADO et al., 1994). Blood samples were collected by intracardiac puncture on the 10th day after the last immunization, and sera were stored at −20 °C until analyzed. Animals from groups A, B, and C were euthanized according to ethical principles in animal experimentation adopted by the Brazilian College of Animal Experimentation (COBEA) and approved by the Ethics Committee on Animal Use (CEUA), protocol number 005965/11.

**Indirect Fluorescence Antibody Test (IFAT)**

The presence of anti-A2 antibodies in immunized mice sera was assessed using amastigote and promastigote forms of *L. infantum* as antigens in an Immunofluorescence Indirect Assay (IFA). To obtain amastigote forms, axenic promastigotes were maintained in culture according to the methodology of Bahrami et al. (2011), whereas promastigotes were obtained according to the methodology described by Oliveira et al. (2008). *Leishmania* sp. promastigotes or amastigotes were washed three times in PBS and resuspended in PBS-buffered formalin (4%) for 30 min. Three additional washes in PBS were performed and the pellet was resuspended in PBS (up to 3-4 × 10⁶ parasites per mL). Slides with 12 previously marked circles (Perfecta LTDA, São Paulo, Brazil) were covered with 10 µL of the solution onto each circle, air-dried, wrapped in a soft paper, and then frozen at −20 °C until use. Slides containing promastigotes or amastigotes were stabilized at room temperature for the IFAT procedure. Sera samples were diluted 1:32, placed on slides covered with *L. infantum*-antigen, and incubated in a moist chamber at 37 °C for 30 min. Slides were washed three times in PBS and incubated with anti-mouse IgG serum conjugated with fluorescein isothiocyanate (Sigma, St. Louis, USA, cat. F0257) diluted 1:64 in PBS containing 1 mg of Evan’s Blue. Slides were washed three times in PBS, once in distilled water, and covered with buffered glycerin using a cover slip, followed by examination in a fluorescent microscope (Olympus, BX-FLA).

**Statistical analysis**

The diagnostic sensitivity, specificity, and accuracy of the single dilution ELISA for the detection of anti-A2 antibodies were determined in comparison to the SLA. Test results were analyzed for inter-assay agreement with SLA using kappa statistics (described in MOHAN et al., 2006).

**Results**

**Expression of A2 recombinant protein**

A2b/A2c-PCR products resulted in a 280 bp fragment. Multiple sequence alignment was performed to compare the identity of the Jaboticabal strain-*L. infantum* A2 amino acid sequence with the amino acid sequence of the same protein from different *Leishmania* sp.-isolates. The A2 recombinant protein was expressed in a soluble form by three different strains of *E. coli* (BL21, ER 2566, and Rosetta). Sufficient amounts of pure protein (334.0 µg/mL for BL21; 328.25 µg/mL for ER 2566; and 411.5 µg/mL for Rosetta) were obtained in the single-step purification by immobilized metal-affinity chromatography. SDS-PAGE and Western blotting analysis using the polyclonal anti-histidine mouse antibodies revealed an 11 KDa molecular weight protein of the recombinant His6-A2 (Figure 1).

**ELISA**

To evaluate the potential of the expressed His6-A2 as a suitable antigen for the serodiagnosis of *L. infantum* infection, the purified His6-A2 was tested in an ELISA using sera samples.
from *L. infantum* -naturally infected dogs, sera samples from dogs from a non-endemic area for leishmaniasis, and sera samples from Leishmune®-vaccinated dogs. The conditions showing an ideal discrimination between negative and positive reference dog sera samples were: an antigen concentration (from BL21 strain) of 2.5 µg/mL in carbonate buffer, pH 9.6, blocked with nonfat dry milk (3%), using PBS Tween 80, sera samples diluted 1:50, and anti-dog IgG alkaline phosphatase antibody diluted 1:4000 (Sigma, St. Louis, USA, cat. A6042). The cut-off value was 0.282 (level 3). From positive controls, positive samples by SLA ELISA, 63% (from a total of 482 samples) were positive by ELISA His-A2 and 93.1% (from a total of 29 samples) of Leishmune®-vaccinated animals were negative by ELISA His-A2 (Figures 2, 3, and 4). Table 1 shows the sensitivity, specificity, and the accuracy of the assay relative to the reference ELISA method using SLA as antigen. The kappa value was 0.47, which represents an agreement of 47% between A2-ELISA and SLA-ELISA from a total of 652 sera samples (vaccinated animals were not included in this analysis). The ELISA levels were determined as shown in Table 2.

**Indirect Fluorescence Antibody Test (IFAT)**

Anti-A2 protein antibodies were detected in slides containing amastigote forms, but not in slides containing promastigote forms, showing that A2 family proteins were found only in this phase (Figure 5). These results confirm the antigenic and immunogenic properties of the expressed protein.

**Discussion**

Many studies have been demonstrated the limitations to identify asymptomatic dogs using the available tests (DYE et al., 1992; REITHINGER et al., 2002; RHALEM et al., 1999). Porrozzi et al. (2007) showed that ELISA based on crude antigens shown minor percentage (30%) for asymptomatic dogs than that ELISA based on recombinant leishmanial antigens rA2 (88%); rK39 and rK26 (66%). Thus, many efforts have been done to development more sensitive, specific and rapid tests to detection of CVL helping in epidemiology and to control the disease (ZIJLSTRA et al., 2001; ATTAR et al., 2001; MOHEBALI et al., 2004; AKHOUNDI et al., 2013).

**Table 1. Relative sensitivity, specificity, and accuracy values of developed ELISA to detect anti-A2 antibodies using SLA as a reference standard.**

<table>
<thead>
<tr>
<th>A2</th>
<th>SLA</th>
<th>+</th>
<th>-</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>304</td>
<td>0</td>
<td>304</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>178</td>
<td>170</td>
<td>348</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>482</td>
<td>170</td>
<td>652</td>
<td></td>
</tr>
</tbody>
</table>

*Sensitivity = 304/482 x 100 = 63%; Specificity = 170/170 x 100 = 100%; Accuracy = 474/652 x 100 = 72.7%. Kappa value = 0.47. SLA = Soluble *Leishmania* antigen (single dilution 1:400).**

**Table 2. Density Optical values for ELISA levels 0-9.**

<table>
<thead>
<tr>
<th>ELISA levels</th>
<th>DO intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0 - 0.115</td>
</tr>
<tr>
<td>1</td>
<td>0.116 - 0.155</td>
</tr>
<tr>
<td>2</td>
<td>0.156 - 0.209</td>
</tr>
<tr>
<td>3</td>
<td>0.210 - 0.282</td>
</tr>
<tr>
<td>4</td>
<td>0.283 - 0.381</td>
</tr>
<tr>
<td>5</td>
<td>0.382 - 0.515</td>
</tr>
<tr>
<td>6</td>
<td>0.516 - 0.696</td>
</tr>
<tr>
<td>7</td>
<td>0.697 - 0.939</td>
</tr>
<tr>
<td>8</td>
<td>0.940 - 1.268</td>
</tr>
<tr>
<td>9</td>
<td>&gt;1.269</td>
</tr>
</tbody>
</table>

**Figure 2. Percentage of seronegative dogs (n = 170) according to ELISA levels using *L. infantum chagasi* soluble and His-A2 as ELISA antigens.**

**Figure 3. Percentage of seropositive naturally infected dogs (n = 482) according to ELISA levels using *L. infantum chagasi* soluble and His-A2 as ELISA antigens.**

**Figure 4. Percentage of sera from Leishmune®-vaccinated dogs (n = 29) according to ELISA levels using *L. infantum chagasi* soluble and His-A2 as ELISA antigens.**
Although A2 protein length ranges from 45 to 100 kDa (ZHANG et al., 1996), the A2 gene isolated by Oliveira et al. (2011) has a length of 495 base pairs. However, after clone sequence analysis, we observed that the amino acid sequence had a predicted signal peptide in the first 26 amino acids. Thus, we excluded this sequence from our construct to avoid solubility problems in the expression, rendering an expressed protein with a final size of 11 kDa.

All three different strains of *E. coli* competent cells used in this study satisfactorily expressed the recombinant A2 protein. The expression of proteins in *E. coli* has many advantages over other systems for cloning and gene expression such as ease of handling, use of relatively simple media, and rapid protein expression. Moreover, the processes of extraction and purification of recombinant proteins is straightforward, which is advantageous for large-scale protein production. Lastly, despite not allowing post-translational modifications, proteins expressed in *E. coli* have been used successfully in diagnostic tests for different diseases in veterinary medicine (MCBRIDE et al., 1999; HUANG et al., 2006).

Although most of the sera samples obtained from *L. infantum*-naturally infected dogs showed high ELISA levels (63% of 482 seropositive dogs), 37% did not show antibodies to the A2 recombinant protein. This lack of A2 antibodies may be related to the phase of the disease at which dogs were sampled and to the fact that all positive samples were tested by serology tests only. Then, we must consider cross-reaction with other species of the parasite. For example, animals infected with *L. braziliensis*, which does not produce the A2 protein and it will be negative in ELISA_A2, but positive in ELISA_SLA. The investigation of A2 expression may indicate the leishmaniasis stage in infected dogs. Additional investigation with symptomatic and asymptomatic dogs, done by parasitological tests, may provide further information for a better understanding of these results.

Porrozzi et al. (2007) showed that serologic tests using the recombinant protein rK39 and rK26 (both from *L. infantum*) were more efficient to identify symptomatic dogs while rA2 (from *Leishmania donovani*) seem to be effective for the serodiagnosis of asymptomatic dogs with the disease. Interestingly, only two of the 29 Leishmune*-vaccinated animals were seropositive by A2_ELISA, and showed ELISA levels near the cut-off point. Dogs from non-endemic areas with previously negative results with *L. infantum*-IFAT and SLA-ELISA studies were also negative by A2_ELISA. Further studies are needed to improve the specificity of the developed assay and more satisfactory results using the A2 protein for serodiagnosis of VL could probably be achieved by using a broader spectrum of proteins instead of a single protein (GHEDIN et al., 1997; PORROZZI et al., 2007; COSTA et al., 2012). Moreover, the high specificity and sensibility of crude antigen compared to the soluble recombinant protein is due to the broad spectrum of protein available for antibody binding.

As already mentioned, A2 family proteins are expressed in the amastigote stage of the parasite, while *Leishmania* is located in the fagoliososomal compartment of the vertebrate host macrophage. In this study, we associated this finding with results obtained in IFAT, in which His-A2 immunized mice sera samples only showed positive results in slides containing amastigotes as antigen.

Moreover, the immunogenicity and antigenicity of the recombinant A2 protein were confirmed by the production of specific antibodies by mice experimentally inoculated with His-A2.
The A2 recombinant protein from *L. donovani* has been tested also in vaccine development including a disposable commercial vaccine, Leish-Tec® (CARVALHO et al., 2002; FERNANDES et al., 2008; TESTASICCA et al., 2014). Further research and novel protocols are being developed to obtain a better characterization of this newly expressed recombinant protein.

**Acknowledgements**

The authors thank FAPESP (Fundaçôo de Amparo à Pesquisa do Estado de São Paulo), Process # 2011/17594-5 and 2011/01961-9 and CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) for fellowship and financial support.

**References**


Rabello Carvalho et al. dx.doi.org/10.1016/j.jmb.2004.05.028. S0001-706X(00)00155-8.


